Haptoglobin 2-2 Genotyping for Refining Standard Cardiovascular Risk Assessment: A Promising Proposition in Need of Validation

J Am Coll Cardiol. 2015 Oct 20;66(16):1800-1802. doi: 10.1016/j.jacc.2015.08.020.

Authors

Benjamin D Horne¹, Jeffrey L Anderson²

Affiliations

¹ Intermountain Heart Institute, Intermountain Medical Center, Salt Lake City, Utah; Department of Internal Medicine, University of Utah, Salt Lake City, Utah. Electronic address: benjamin.horne@imail.org.
² Intermountain Heart Institute, Intermountain Medical Center, Salt Lake City, Utah; Department of Internal Medicine, University of Utah, Salt Lake City, Utah.

PMID: 26483104
DOI: 10.1016/j.jacc.2015.08.020

No abstract available

Keywords: basket trial; clinical decision rule; genotype-guided therapy; sequence-stratified risk prediction.

Publication types

Editorial
Comment

MeSH terms

Biomarkers*
Coronary Disease / genetics*
Female
Glycated Hemoglobin / analysis*
Haptoglobins / genetics*
Humans
Male

Substances

Biomarkers
Glycated Hemoglobin A
Haptoglobins